2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. Apolipoprotein Inhibitor

Apolipoprotein Inhibitor

Apolipoprotein Isoform Comparison

Apolipoprotein Inhibitors (15):

Cat. No. Product Name Effect Purity
  • HY-108764
    Mipomersen sodium
    		Inhibitor
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).
  • HY-132820
    Inaxaplin
    		Inhibitor 98.78%
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
  • HY-145727
    Volanesorsen
    		Inhibitor
    Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-164740A
    Plozasiran sodium
    		Inhibitor
    Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
  • HY-164740
    Plozasiran
    		Inhibitor
    Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.
  • HY-112798
    PH-002
    		Inhibitor 98.78%
    PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.
  • HY-145727A
    Volanesorsen sodium
    		Inhibitor
    Volanesorsen sodium is an antisense oligonucleotide thay targes Apolipoprotein C-III (APOC3) mRNA. Volanesorsen sodium is used for the study of familial chylomicronemia syndrome.
  • HY-P99105
    Anselamimab
    		Inhibitor 98.96%
    Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to serum amyloid A1 (SAA1).
  • HY-141885
    APOL1-IN-1
    		Inhibitor 99.62%
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
  • HY-RS00846
    APOC3 Human Pre-designed siRNA Set A
    		Inhibitor

    APOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-147425
    Zerlasiran
    		Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-153491
    Olezarsen
    		Inhibitor
    Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
  • HY-153491A
    Olezarsen sodium
    		Inhibitor
    Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
  • HY-148647
    Mipomersen
    		Inhibitor
    Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).